126 related articles for article (PubMed ID: 38511268)
1. Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma.
Flanagan L; Coughlan A; Cosgrove N; Roe A; Wang Y; Gilmore S; Drozdz I; Comerford C; Ryan J; Minihane E; Parvin S; O'Dwyer M; Quinn J; Murphy P; Furney S; Glavey S; Chonghaile TN; ; ;
Haematologica; 2024 Mar; ():. PubMed ID: 38511268
[TBL] [Abstract][Full Text] [Related]
2. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
3. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
4. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
5. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC
Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729
[TBL] [Abstract][Full Text] [Related]
6. The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA.
Weller S; Toennießen A; Schaefer B; Beigl T; Muenchow A; Böpple K; Hofmann U; Gillissen BF; Aulitzky WE; Kopp HG; Essmann F
Cell Death Discov; 2022 Apr; 8(1):215. PubMed ID: 35443750
[TBL] [Abstract][Full Text] [Related]
7. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
Bajpai R; Matulis SM; Wei C; Nooka AK; Von Hollen HE; Lonial S; Boise LH; Shanmugam M
Oncogene; 2016 Jul; 35(30):3955-64. PubMed ID: 26640142
[TBL] [Abstract][Full Text] [Related]
8. Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.
Juarez D; Buono R; Matulis SM; Gupta VA; Duong M; Yudiono J; Paul M; Mallya S; Diep G; Hsin P; Lu A; Suh SM; Dong VM; Roberts AW; Leverson JD; Jalaluddin M; Liu Z; Bueno OF; Boise LH; Fruman DA
Cancer Res Commun; 2023 Dec; 3(12):2497-2509. PubMed ID: 37956312
[TBL] [Abstract][Full Text] [Related]
9. Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
Algarín EM; Quwaider D; Campos-Laborie FJ; Díaz-Tejedor A; Mogollón P; Vuelta E; Martín-Sánchez M; San-Segundo L; González-Méndez L; Gutiérrez NC; García-Sanz R; Paíno T; De Las Rivas J; Ocio EM; Garayoa M
Cells; 2021 Mar; 10(3):. PubMed ID: 33806619
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience.
Giudice V; Serio B; Ferrara I; Manzo P; Gorrese M; Pepe R; Bertolini A; D'Alto F; Verdesca F; Langella M; Filippelli A; Selleri C
Front Pharmacol; 2022; 13():1052060. PubMed ID: 36618908
[TBL] [Abstract][Full Text] [Related]
11. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
12. A same-day assay predicts apoptotic response to combined BCL-2 and MCL-1 BH3-mimetic targeting in multiple myeloma cells.
Grundy M; Al-Kaisi F; Cull J; Williams C; Smith D; Seedhouse CH
EJHaem; 2021 Feb; 2(1):40-47. PubMed ID: 35846088
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH
Leukemia; 2016 May; 30(5):1086-93. PubMed ID: 26707935
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma.
Zhao X; Bodo J; Chen R; Durkin L; Souers AJ; Phillips DC; Hsi ED
EJHaem; 2020 Jul; 1(1):161-169. PubMed ID: 35847704
[TBL] [Abstract][Full Text] [Related]
17. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.
Satta T; Li L; Chalasani SL; Hu X; Nkwocha J; Sharma K; Kmieciak M; Rahmani M; Zhou L; Grant S
Clin Cancer Res; 2023 Apr; 29(7):1332-1343. PubMed ID: 36652560
[TBL] [Abstract][Full Text] [Related]
18. Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA.
Fairchild CK; Floros KV; Jacob S; Coon CM; Puchalapalli M; Hu B; Harada H; Dozmorov MG; Koblinski JE; Smith SC; Domson G; Leverson JD; Souers AJ; Takebe N; Ebi H; Faber AC; Boikos SA
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065859
[TBL] [Abstract][Full Text] [Related]
19. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
20. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
